Page 1

ADAGENE Exhibit 99.1 Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates Randomized Phase 2 trial in microsatellite stable colorectal cancer ( MSS CRC ) ongoing , with results expected in 1H 2027 ; potential registration trial expected in 2027 once recommended dose regimen has been established Data reported at AACR from triple combination therapy in 1L hepatocellular carcinoma ( HCC ) and late - line MSS CRC highlights muzastotug's potential as a backbone combination treatment for multiple tumor types across all lines of therapy Initiated dosing in a global Phase 1/2 basket trial evaluating muzastotug in combination with a next - generation investigational IO agent through a clinical collaboration with Sanofi Investigator - initiated Phase 2 trial of muzastotug in neoadjuvant setting for colorectal cancer is ongoing Cash and cash equivalents of $ 127.9 million include proceeds of public offering in April 2026 ; provide runway into late 2028 SAN DIEGO , Calif . and SUZHOU , China , August 12 , 2026 - Adagene Inc. ( " Adagene ” ) ( Nasdaq : ADAG ) , a platform - driven , clinical - stage biotechnology company transforming the discovery and development of novel antibody - based therapies , today reported financial results for the six months ended June 30 , 2026 , and provided corporate updates . " The first half of 2026 was a period of meaningful advances for the company , as our lead program , muzastotug , a masked , anti - CTLA - 4 SAFEbody , continues to demonstrate compelling efficacy and a favorable safety profile in MSS CRC and HCC , " said Peter Luo , Ph.D. , CEO and President of R & D at Adagene . " The strength of muzastotug as a potential backbone therapy continues to be recognized with recent collaborations and the clinical data to date demonstrates the enhanced safety of muzastotug relative to legacy CTLA - 4 therapies , even at approximately ten times higher doses . This enhanced safety allows muzastotug to be used as a potential backbone therapy in combination with pembrolizumab and / or other standard of care therapies , such as fruquintinib . We remain encouraged by the durable benefit we are seeing . ” " We also welcomed Peter Lebowitz to our Scientific and Strategic Advisory Board , further strengthening the clinical expertise guiding our programs ; ” continued Dr. Luo . “ The equity offering in April brought in new investors and extended our cash runway into late 2028 , allowing us to accelerate our pipeline and deliver on our mission to transform cancer immunotherapy for patients . " PIPELINE HIGHLIGHTS Muzastotug ( ADG126 ) Phase 1b / 2 study in combination with Merck's ( known as MSD outside of the United States and Canada ) anti - PD - 1 therapy , KEYTRUDA® ( pembrolizumab ) , in patients with advanced microsatellite stable colorectal cancer ( MSS CRC ) with no liver metastases . 1